Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

60.03  -1.39 (-2.26%)

After market: 60.03 0 (0%)

Fundamental Rating

7

HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making HALO a very profitable company, without any liquidiy or solvency issues. HALO has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make HALO a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
In the past year HALO had a positive cash flow from operations.
Each year in the past 5 years HALO has been profitable.
In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

With an excellent Return On Assets value of 21.52%, HALO belongs to the best of the industry, outperforming 98.94% of the companies in the same industry.
Looking at the Return On Equity, with a value of 122.06%, HALO belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 23.00%, HALO belongs to the top of the industry, outperforming 99.12% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is above the industry average of 14.24%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(23.00%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.52%
ROE 122.06%
ROIC 23%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

Looking at the Profit Margin, with a value of 43.74%, HALO belongs to the top of the industry, outperforming 99.12% of the companies in the same industry.
HALO's Profit Margin has declined in the last couple of years.
HALO's Operating Margin of 54.32% is amongst the best of the industry. HALO outperforms 99.82% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
The Gross Margin of HALO (84.30%) is better than 86.93% of its industry peers.
In the last couple of years the Gross Margin of HALO has grown nicely.
Industry RankSector Rank
OM 54.32%
PM (TTM) 43.74%
GM 84.3%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
HALO has less shares outstanding than it did 1 year ago.
HALO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HALO has an improved debt to assets ratio.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

HALO has an Altman-Z score of 4.85. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.85, HALO belongs to the top of the industry, outperforming 80.57% of the companies in the same industry.
HALO has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as HALO would need 3.21 years to pay back of all of its debts.
The Debt to FCF ratio of HALO (3.21) is better than 93.99% of its industry peers.
HALO has a Debt/Equity ratio of 4.14. This is a high value indicating a heavy dependency on external financing.
HALO has a Debt to Equity ratio of 4.14. This is amonst the worse of the industry: HALO underperforms 83.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.14
Debt/FCF 3.21
Altman-Z 4.85
ROIC/WACC2.52
WACC9.12%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

HALO has a Current Ratio of 7.80. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HALO (7.80) is better than 73.67% of its industry peers.
HALO has a Quick Ratio of 6.78. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.78, HALO is in the better half of the industry, outperforming 68.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.8
Quick Ratio 6.78
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.16% over the past year.
The Earnings Per Share has been growing by 30.12% on average over the past years. This is a very strong growth
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 22.46%.
HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)52.16%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%53.66%
Revenue 1Y (TTM)22.46%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%29.55%

3.2 Future

HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.06% yearly.
Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 11.27% on average per year.
EPS Next Y24.79%
EPS Next 2Y26.9%
EPS Next 3Y24.66%
EPS Next 5Y16.06%
Revenue Next Year19.16%
Revenue Next 2Y21.65%
Revenue Next 3Y19.98%
Revenue Next 5Y11.27%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 14.19, HALO is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.82% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (27.85), we can say HALO is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 11.37, the valuation of HALO can be described as reasonable.
Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 96.47% of the companies in the same industry.
HALO's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.77.
Industry RankSector Rank
PE 14.19
Fwd PE 11.37
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.47% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 95.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.83
EV/EBITDA 12.67
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 24.66% in the coming years.
PEG (NY)0.57
PEG (5Y)N/A
EPS Next 2Y26.9%
EPS Next 3Y24.66%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/1/2025, 9:06:46 PM)

After market: 60.03 0 (0%)

60.03

-1.39 (-2.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18 2025-02-18/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners99.23%
Inst Owner Change0.03%
Ins Owners0.81%
Ins Owner Change0.77%
Market Cap7.42B
Analysts77.33
Price Target70.96 (18.21%)
Short Float %7.88%
Short Ratio6.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.72%
Min EPS beat(2)6.64%
Max EPS beat(2)26.79%
EPS beat(4)4
Avg EPS beat(4)15.64%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)9.66%
EPS beat(16)13
Avg EPS beat(16)12.34%
Revenue beat(2)2
Avg Revenue beat(2)7.32%
Min Revenue beat(2)1.36%
Max Revenue beat(2)13.28%
Revenue beat(4)3
Avg Revenue beat(4)5.36%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)13.28%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)6
Avg Revenue beat(12)1.1%
Revenue beat(16)9
Avg Revenue beat(16)3.23%
PT rev (1m)5.23%
PT rev (3m)8.49%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)-9.94%
EPS NY rev (1m)0.58%
EPS NY rev (3m)6.05%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)-10.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.74%
Valuation
Industry RankSector Rank
PE 14.19
Fwd PE 11.37
P/S 7.3
P/FCF 15.83
P/OCF 15.48
P/B 20.38
P/tB N/A
EV/EBITDA 12.67
EPS(TTM)4.23
EY7.05%
EPS(NY)5.28
Fwd EY8.79%
FCF(TTM)3.79
FCFY6.32%
OCF(TTM)3.88
OCFY6.46%
SpS8.22
BVpS2.95
TBVpS-3.68
PEG (NY)0.57
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 21.52%
ROE 122.06%
ROCE 28.66%
ROIC 23%
ROICexc 33.33%
ROICexgc 86.86%
OM 54.32%
PM (TTM) 43.74%
GM 84.3%
FCFM 46.13%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 4.14
Debt/FCF 3.21
Debt/EBITDA 2.38
Cap/Depr 13.15%
Cap/Sales 1.05%
Interest Coverage 52.2
Cash Conversion 75.71%
Profit Quality 105.47%
Current Ratio 7.8
Quick Ratio 6.78
Altman-Z 4.85
F-Score9
WACC9.12%
ROIC/WACC2.52
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)52.16%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%53.66%
EPS Next Y24.79%
EPS Next 2Y26.9%
EPS Next 3Y24.66%
EPS Next 5Y16.06%
Revenue 1Y (TTM)22.46%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%29.55%
Revenue Next Year19.16%
Revenue Next 2Y21.65%
Revenue Next 3Y19.98%
Revenue Next 5Y11.27%
EBIT growth 1Y62.13%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3Y32.05%
EBIT Next 5Y15.57%
FCF growth 1Y25.47%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y23.29%
OCF growth 3Y16.96%
OCF growth 5YN/A